Canada Markets close in 3 hrs 24 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
50.67+0.75 (+1.49%)
As of 12:36PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close49.92
Open49.87
Bid50.56 x 1000
Ask50.57 x 900
Day's Range49.91 - 50.83
52 Week Range38.48 - 61.71
Volume8,307,212
Avg. Volume28,420,171
Market Cap284.376B
Beta (5Y Monthly)0.62
PE Ratio (TTM)14.47
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.60 (2.93%)
Ex-Dividend DateJan 27, 2022
1y Target EstN/A
  • Business Wire

    Pfizer to Acquire Biohaven Pharmaceuticals

    NEW YORK & NEW HAVEN, CONN., May 10, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.

  • GlobeNewswire

    Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

    BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information the Ag

  • Business Wire

    Pfizer Reports First-Quarter 2022 Results

    NEW YORK, May 03, 2022--Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance, including its guidance for Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and for Paxlovid, its oral COVID-19 treatment, despite unfavorable impacts from foreign exchange.